KYONGBO PHARMACEUTICAL CO., LTD.
Financials
Valuation Metrics
KYONGBO PHARMACEUTICAL CO., LTD.'s Market Cap is ₩1303B. At end of 2025 it was ₩1379B. Ranked #1107 of 2,421 in KR market (top 46%), #531 of 781 on KOSPI (top 68%), #126 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 130.29B KRW | KR#1,107/2,421 Sec#126/231 |
| Revenue | 279.55B KRW | KR#859/2,421 Sec#40/231 |
| Net Income | 5.06B KRW | KR#1,204/2,421 Sec#79/231 |
| Total Assets | 367.57B KRW | KR#917/2,421 Sec#57/231 |
| Net Assets | 146.99B KRW | KR#1,151/2,421 Sec#82/231 |
| Employees | 525 | KR#476/2,421 Sec#39/231 |
| Value | ||
| P/E | 25.77x | KR#1,263/2,421 Sec#75/231 |
| P/B | 0.89x | KR#1,355/2,421 Sec#85/231 |
| PEG | 0.02x | KR#200/2,421 Sec#10/231 |
| P/S | 0.47x | KR#881/2,421 Sec#39/231 |
| EV/EBITDA | 105.89x | KR#1,497/2,421 Sec#99/231 |
| FCF Yield | -26.16% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 3.44% | KR#1,294/2,421 Sec#89/231 |
| ROA | 1.38% | KR#1,339/2,421 Sec#95/231 |
| Op. Margin | 0.94% | KR#1,505/2,421 Sec#105/231 |
| Revenue Growth | 14.83% | KR#697/2,421 Sec#67/231 |
| Earnings Growth | 1151.09% | KR#56/2,421 Sec#5/231 |
| Financial Health | ||
| Debt Ratio | 150.06% | KR#1,902/2,421 Sec#209/231 |
| Total Debt | 155.44B KRW | KR#595/2,421 Sec#33/231 |
| FCF | -34.08B KRW | KR#2,014/2,421 Sec#195/231 |
| Cash | 6.92B KRW | KR#1,883/2,421 Sec#168/231 |
| Current Ratio | 0.88x | KR#1,860/2,421 Sec#181/231 |
| Net Debt/EBITDA | 56.40x | KR#1,492/2,421 Sec#104/231 |
| Dividend | ||
| Div. Yield | 0.92% | KR#1,139/2,421 Sec#66/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -9.02% | KR#950/2,421 Sec#61/231 |
| 1M Return | 7.28% | KR#612/2,421 Sec#41/231 |
| From 52W High | -41.40% | KR#988/2,421 Sec#69/231 |
| 1Y MDD | -42.16% | KR#666/2,421 Sec#49/231 |
| Trading | ||
| Volume | 9,918 shares | KR#1,918/2,421 Sec#186/231 |
| Trading Value | 54.0M KRW | KR#1,807/2,421 Sec#186/231 |
| Foreign Own. | 2.25% | KR#1,545/2,421 Sec#146/231 |
| Per Share | ||
| EPS | 211 KRW | KR#1,267/2,421 Sec#85/231 |
| BPS | 6,148 KRW | KR#1,347/2,421 Sec#94/231 |
Company Info
Established in 1987 as a specialized Active Pharmaceutical Ingredient (API) company, the company expanded into finished pharmaceutical products in 2002 and was renamed Kyung Bo Pharm. in 2007. It markets specialized pharmaceuticals, including cardiovascular drugs and inhalant anesthetics, along with various over-the-counter drugs, while exporting cephalosporin antibiotics like Ceftriaxone domestically and internationally from its API division. Kyung Bo Pharm. is diversifying into medical devices and animal health products, such as animal pharmaceuticals and nutritional supplements. Headquartered in Asan-si, Chungcheongnam-do, the company is developing ADC (Antibody-Drug Conjugate) anticancer drug technologies for entry into the global ADC CDMO market.